Vaccitech Ltd.. (1/15/18). "Press Release: Vaccitech Secures £20m Series A with GV, OSI and Sequoia China".

	Organisation	Vaccitech Ltd.
	Group	Vaccitech (Group)
	Organisation 2	GV (formerly Google Ventures)
	Group	Alphabet (formerly Google) (Group)
	Product	vaccine technology
	Product 2	venture capital
	Index term	Vaccitech–SEVERAL: investment, 201801 financing round Series A £20m with GV + Sequoia China + OSI + Neptune Ventures
	Person	Evans, Thomas G. (Tom) (Vaccitech 201908– CSO before CEO before Vical + Novartis + Aeras)
	Person 2	Hulme, Tom (Alphabet 201603 General Partner at GV)

Vaccitech, an Oxford University spinout company developing a universal flu vaccine, among other vaccine-related products, has secured £20m ($27.1m) in Series A financing.

The round was co-led by new investors GV, Sequoia China, and existing backer Oxford Sciences Innovation, which manages a £600m fund aimed at Oxford University spinouts. Neptune Ventures joined in participation. In total, Vaccitech has now raised £30m since inception in 2016.

Vaccitech is currently a clinical stage company, with six total products that are based on inducing cellular immune responses using non-replicating viral vectors for treatment or prophylaxis against diseases at various stages. The CD8+ T-cell responses induced by the proprietary platform are among the highest reported in any human trials.

The portfolio of the company includes:

> A universal influenza vaccine in evaluation in a Phase 2b efficacy trial, in which 862 people are enrolled in the first year of a two-year study. At present, there are currently between three to five million new cases of influenza each year, resulting in 250,000 to 500,000 deaths per annum, mostly in the elderly population. Vaccitech’s universal vaccine recognises the conserved proteins of the virus and is active against all influenza A strains, including avian ones.

> Vaccitech’s prostate cancer therapeutic is current at Phase I, and has shown high level immune T cell responses to the self-antigen 5T4, indicating strong potential applicability of the vaccine platform to cancer in general. A Phase 2 study combining the vaccine platform with a checkpoint inhibitor will begin in metastatic prostate disease in early 2018.

> A Middle East Respiratory Syndrome (MERS) prophylactic is currently beginning Phase 1 studies at Oxford University.

> A Human Papillomavirus (HPV) therapeutic, a Hepatitis B (HBV) therapeutic, and another infectious disease asset are in late preclinical development.

The company, spun out by Oxford University Innovation in 2016, is commercialising the research of vaccine development specialists Adrian Hill and Sarah Gilbert, who developed the underpinning technology at Oxford University’s Jenner Institute. The work of Hill and Gilbert attracted Thomas Evans as its CEO, who relocated from the US to the UK for the role. Evans is a vaccine veteran bringing with him over a 15 years’ experience at Vical, as Global Head of Infectious Diseases Research at Novartis, and as CSO and CEO at the tuberculosis vaccine-focused biotech Aeras. Vaccitech has also added vaccine veteran Pierre Morgon to its Board of Directors.

Currently based at the Oxford Science Park, Vaccitech will use the funding to expand its business, develop its lab structure, and to push its influenza and prostate cancer programmes through Phase II by the end of 2019, and move three other programs into the clinic.

Tom Evans, Chief Executive Officer at Vaccitech said:
“When you look at the 250 million people chronically infected with hepatitis B globally, or the number of people killed by the flu each year, it becomes clear just how much potential impact Vaccitech’s portfolio of vaccine products could have on the world. You add Oxford into the mix, where you have unprecedented ability to do advance products through outstanding vaccine science and tremendous translational medicine capability, and Vaccitech is clearly well positioned to have an important impact on global health.”

Tom Hulme, General Partner at GV, added:
“Vaccitech’s world class team have achieved an incredible amount with relatively little funding to date – the T-cell responses to the company’s viral vector platform are among the highest that have been achieved in man – we look forward to it being applied to tackle multiple human diseases.”

Record changed: 2023-06-05